Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice-Reference-Cited by-同舟云学术

Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice

Published:2016-03-10 Issue:3 Volume:11 Page:e0150756
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chiba Yumiko,Yamada Tetsuya,Tsukita Sohei,Takahashi Kei,Munakata Yuichiro,Shirai Yuta,Kodama Shinjiro,Asai Yoichiro,Sugisawa Takashi,Uno Kenji,Sawada Shojiro,Imai Junta,Nakamura Kazuhiro,Katagiri Hideki

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference24 articles.

1. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus;V Vallon;Annu Rev Med,2015

2. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects;E Ferrannini;Nat Rev Endocrinol,2012

3. Renal glucose reabsorption inhibitors to treat diabetes;CJ Bailey;Trends Pharmacol Sci,2011

4. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes;JF List;Diabetes Care,2009

5. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet;SP Vickers;Diabetes Metab Syndr Obes,2014

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity;Frontiers in Cardiovascular Medicine;2024-05-16

2. Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition;Diabetes & Metabolism Journal;2023-11-30

3. SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection;Current Molecular Pharmacology;2023-11-28

4. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus;Current Medicinal Chemistry;2023-10-19

5. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model;European Journal of Pharmacology;2023-10